Lynx Biosciences (LynxBio) is developing technologies to predict clinical treatment response for multiple myeloma (MM) and blood cancer patients. LynxBio’s product, MicroC3™, is an assay that rapidly analyzes the therapeutic response of patients’ tumor cells with their own non-tumor cells. MicroC3 is a more accurate reflection of the unique biology in individual patients and is currently the only assay enabling analysis of blood cancers. MicroC3 is rapidly performed within 3 days of a standard of care biopsy. LynxBio's goal is to improve overall survival and quality of life for patients by reducing ineffective therapies.